Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis

OBJECTIVE: To assess the effectiveness of methotrexate (MTX) in the treatment of juvenile idiopathic arthritis (JIA) associated uveitis, which is still one of the most common causes of visual impairment. METHODS: A retrospective chart review of patients with the diagnosis of uveitis associated with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2005-02, Vol.32 (2), p.362-365
Main Authors: FOELDVARI, IVAN, WIERK, ANGELA
Format: Article
Language:English
Subjects:
Adolescent
Arthritis, Juvenile - complications
Arthritis, Juvenile - drug therapy
Arthritis, Juvenile - pathology
Biological and medical sciences
Child
Child, Preschool
Chronic Disease
Dermatology
Diseases of the osteoarticular system
Drug Resistance
Female
Glucocorticoids - therapeutic use
Humans
Immunosuppressive Agents - therapeutic use
Infant
Inflammatory joint diseases
Male
Medical sciences
Methotrexate - therapeutic use
Ophthalmology
Psoriasis. Parapsoriasis. Lichen
Remission Induction
Retrospective Studies
Treatment Outcome
Uvea diseases
Uveitis - complications
Uveitis - drug therapy
Uveitis - pathology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: To assess the effectiveness of methotrexate (MTX) in the treatment of juvenile idiopathic arthritis (JIA) associated uveitis, which is still one of the most common causes of visual impairment. METHODS: A retrospective chart review of patients with the diagnosis of uveitis associated with JIA between July 1, 2002, and December 31, 2002. RESULTS: Four hundred sixty-seven patients with JIA were followed. Thirty-eight had uveitis: 31 associated with oligoarticular JIA and 7 with psoriatic JIA. Twenty-five of the 38 patients received MTX; in 23 patients uveitis was the indication for MTX therapy. In the MTX treated group 46/50 eyes had uveitis, the mean (range) age at onset of uveitis was 7.82 years (1.8-15.8), and the mean age at onset of arthritis was 7.25 years (1.25-15.7). MTX treatment was started an average of 11.4 months (0-72) after the onset of uveitis. The mean MTX dose was 15.6 mg/m2. Remission occurred after 4.25 months (1-12). Mean duration of remission was 10.3 months (3-27). The total duration of MTX therapy was 661 months and patients were in remission for 417/661 months. In 6 patients MTX was discontinued after 12 months of remission. Four patients were still in remission after 7.5 months (1-14). CONCLUSION: MTX seems to be an effective therapy for JIA associated uveitis.
ISSN:0315-162X
1499-2752